In re Coordinated Pretrial Proceedings in Antibiotic Antitrust Actions

410 F. Supp. 669, 1974 U.S. Dist. LEXIS 9407
District Court, D. Minnesota·Decided March 21, 1974·No. No. 4-71 Civ. 435·Published·Cited by 2 cases

Opinion

MEMORANDUM OPINION APPROVING SETTLEMENTS

MILES W. LORD, District Judge.

The parties have moved the Court pursuant to Rule 23(e) of the Federal Rules of Civil Procedure for approval of the proposed settlement of these class actions.

BACKGROUND

These six class actions are a part of the more than 150 actions brought against defendants since 1968 alleging that defendants, beginning in 1953, conspired to and did monopolize the manufacture, sale and distribution of broad spectrum antibiotics and broad spectrum antibiotic products (BSA),1 and conspired [671]*671to restrain trade in the manufacture, sale and distribution of BSA within interstate and foreign commerce.

All of the 150 actions related in some fashion to the 1958 F.T.C. hearing and to the 1961 criminal indictment against certain of the defendants.

A. F.T.C. and Criminal Actions.

Commencing in 1953, the Federal Trade Commission initiated an investigation into the business conduct, practices and management of corporations engaged in the production, sale or distribution of antibiotic drugs. In July of 1958, the Federal Trade Commission issued a complaint charging the defendants, American Cyanamid Company, Chas. Pfizer & Co., Inc., Bristol-Myers Company, Olin Mathieson Chemical Corporation (Squibb), and the Upjohn Company, with unfair methods of competition and unfair acts and practices in the sale of antibiotics, all in violation of Section 5 of the Federal Trade Commission Act (15 U.S.C. § 45).2 Following the taking of evidence, the hearing examiner filed his opinion, which was taken to the full commission and the commission required compulsory licensing under the patents held for the purpose of making tetracycline.3 This decision was appealed to the United States Court of Appeals for the Sixth Circuit, which Court in June of 1966 handed down its decision. American Cyanamid Co. v. F. T. C., 363 F.2d 757 (6th Cir. 1966). The Court required the taking of additional testimony and the matter was remanded to the commission. Following the testimony, a new hearing examiner rendered his opinion, which was again taken to the full commission. The commission rendered its opinion, which was again appealed to the Sixth Circuit and in September of 1968, the Court handed down its decision holding the testimony of Examiner Lidoff supported the findings of misconduct before the Patent Office and justified the compulsory licensing order of the commission. Charles Pfizer & Co. v. F. T. C., 401 F.2d 574 (6th Cir. 1968), cert. denied, 394 U.S. 920, 89 S.Ct. 1195, 22 L.Ed.2d 453.

In 1961, an indictment was returned by the Grand Jury of the Southern District of New York (61 Cr. 772), naming Pfizer, Cyanamid and Bristol and the chief executives of each company as defendants and additionally naming Squibb and Upjohn as co-conspirators. The indictment charged that the defendants, pursuant to a conspiracy, had misled the Patent Office, used patents to exclude competitors and fix prices.

Trial of the criminal action took place in November and December of 1967, before a jury, and a verdict of guilty on all counts as to the defendants Pfizer, Cyan-amid and Bristol was returned. A judgment of conviction was appealed and was reversed with directions for a new trial. United States v. Chas. Pfizer & Co., 426 F.2d 32 (2d Cir. 1970). The matter was retried before Judge John Cannella, sitting without a jury. On November 30, 1973, Judge Cannella returned his verdict, finding each defendant not guilty on all counts of the indictment. See, United States v. Chas. Pfizer & Co., 1972-73 Trade Reg.Rep. § 74812.

B. The Civil Actions.

Following return of the jury verdict in the criminal proceedings of December 1967, more than 150 civil actions were filed against the defendants, claiming treble damages on account of alleged antitrust violations in the sale of broad spectrum antibiotic drugs. A large number of those actions, including the actions filed by the six states herein, were brought as class actions under Rule 23(b)(3) of the Federal Rules of Civil Procedure.

On November 19, 1968, the Judicial Panel on Multidistrict Litigation transferred all of the broad spectrum antibi[672]*672otic cases filed throughout the United States to the Southern District of New York, pursuant to 28 U.S.C. § 1407, where they were consolidated for coordinated pretrial discovery before Judge Inzer B. Wyatt. In re Antibiotic Drugs, 295 F.Supp. 1402 (Jud.Pan.Mult.Lit.1968).

Under date of February 6, 1969, (later modified under date of May 9, 1969), the defendants made a written offer of $100,000,000 in settlement of all of the claims of states, counties, cities and their political subdivisions and agencies, and any other government entities, excluding the federal government, arising out of their purchases or payments for broad spectrum antibiotics, as well as the claims of wholesalers, retailers and individual consumers arising out of such purchases, including the claims of states as parens patriae on behalf of their citizens, or on behalf of classes including the state as a consumer and all other consumers in the state.

The settlement offer was accepted by most of the plaintiffs, including 48 state plaintiffs, and on May 26, 1969, Judge Wyatt entered an order which began the administration of the proposed settlement.4 That order provided that any of the plaintiff states not accepting the offer of settlement could, by notice, exclude itself and the classes which it proposed to represent from the proposed settlement.

The six states herein plus the State of North Carolina rejected this settlement offer and elected to continue with the litigation. The settlement offer was reduced proportionately to approximately $85,000,000.

By Pretrial Order No. 1, dated February 24, 1970, Judge Wyatt divided the non-settling cases into four categories: (1) city, county, state and the United States Government cases (CCS cases); (2) farm cases; (3) miscellaneous cases; and (4) hospital cases. The counsel of record for each category of cases were designated as a committee of counsel. Each committee of counsel selected five of its members to participate on a Plaintiffs’ National Steering Committee (PNSC), which was charged with the coordination of the plaintiffs’ discovery efforts.

The administration of the $85,000,000 settlement accepted by 43 of the states and certain other classes became increasingly burdensome upon Judge Wyatt. On December 2, 1970, the Judicial Panel, with Judge Wyatt’s consent and recommendation assigned the 60 actions remaining in a litigating status to this Judge under special assignment to the Southern District of New York.5

Free access — add to your briefcase to read the full text and ask questions with AI

In re Coordinated Pretrial Proceedings in Antibiotic Antitrust Actions, 410 F. Supp. 669, 1974 U.S. Dist. LEXIS 9407 (mnd 1974).

410 F. Supp. 669 (In re Coordinated Pretrial Proceedings in Antibiotic Antitrust Actions) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Muehler v. Land O'Lakes, Inc.
617 F. Supp. 1370 (D. Minnesota, 1985)
Barnett v. Pritzker
73 F.R.D. 430 (S.D. New York, 1977)